Article
Pharmacology & Pharmacy
Mac Arturo Murillo-Fernandez, Ernesto Montero-Zeledon, Ariadna Abdala-Saiz, Jose Roberto Vega-Baudrit, Andrea Mariela Araya-Sibaja
Summary: A study was conducted to investigate drug-drug and drug-excipient interactions and compatibilities in two fixed-dose combination products containing olmesartan medoxomil/hydrochlorothiazide. The results showed weak solid-state interactions but they did not affect the performance of the final products.
Article
Spectroscopy
Amira H. Kamal, Sherin F. Hammad, Doaa N. Kamel
Summary: Four UV chemometric spectrophotometric techniques were developed and tested for determination of AML and OLM, achieving linearity in the concentration range of 2-25 μg/mL. The methods were found to be uncomplicated, reproducible, efficient, and cost-effective for determining the drugs in laboratory samples and commercial pharmaceutical formulations.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
(2022)
Article
Biochemical Research Methods
Vishnu Murthy Marisetti, Prakash Katakam, Vijaya Krishna Siddhani, Naresh Kumar Katari
Summary: The current work focuses on the development and validation of a stability-indicating UPLC method for the determination of key components and their degradation products in a triple-combination tablet dosage form. The method showed good analytical performance, specificity, and robustness, making it suitable for drug product analysis.
BIOMEDICAL CHROMATOGRAPHY
(2021)
Review
Medicine, General & Internal
Lakshya Kumar, Sundal Khuwaja, Aanand Kumar, Unaib Ahmed Memon, Munesh Kumar, Arpana Ashok, Manisha Lohana, Ahmed Qudoos, Maham Kashif, Mahima Khatri, Satesh Kumar, F. N. U. Sapna, Arjan Dass, Giustino Varrassi
Summary: This study compares the effectiveness and safety of azilsartan-medoxomil/chlorthalidone (AZI-M/CT) and olmesartan-medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with hypertension. The study finds that AZI-M/CT is more effective than OLM/HCTZ in reducing diastolic blood pressure, but there is no significant difference in systolic blood pressure. Furthermore, the AZI-M/CT group has a higher incidence of major adverse events compared to the OLM/HCTZ group, but there is no significant difference in mortality risk.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2023)
Article
Medicine, Research & Experimental
Jaewon Oh, Wonho Kim, Gee-Hee Kim, Hack-Lyoung Kim, Sang-Don Park, Kyung Wan Min, Dongkeun Hyun, Jun Hwa Hong, Soo Lim, Jinho Shin
Summary: This study assessed the real-world safety and effectiveness of an SPC containing olmesartan, amlodipine, and hydrochlorothiazide in South Korean patients with hypertension and cardiovascular risk factors. The results showed that the therapy led to a significant reduction in blood pressure and had a high control rate.
ADVANCES IN THERAPY
(2023)
Article
Pharmacology & Pharmacy
Binny Mehta, H. Joshi, U. Shah, P. Patel
Summary: In this study, a numerical method based on spectrophotometric data and partial least squares multivariate calibration was evaluated for the simultaneous determination of olmesartan medoxomil and hydrochlorothiazide. The results showed that the proposed method is simple, rapid, and can be used as an alternative analysis tool for drug quality control.
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2022)
Article
Peripheral Vascular Disease
Zhaoqiang Cui, Zhaohui Qiu, Wenli Cheng, Wei Hu, Genshan Ma, Xiaojun Cai, Yafei Jin, Yi Zhao, Liqun He, Ying Li, Peili Bu, Xiaoping Chen, Ruxing Wang, Lin Chen, Peng Dong, Liuliu Feng, Xuebin Han, Mei Hong, Yinglong Hou, Minlei Liao, Mingliang Wang, Xiaoyan Wang, Jianhong Xie, Yawei Xu, Zhenxing Wang, Kai Huang, Yongle Li, Dongsheng Li, Xiaojun Ji, Jing Huang, Jun Wang, Danhong Fang, Jian'an Wang, Lijiang Tang, Yingwu Liu, Guosheng Fu, Juan Du, Ling Wang, Mengqi Liu, Junbo Ge
Summary: This study evaluates the efficacy and safety of OM-AML tablet in patients with essential hypertension. The results show that the tablet effectively reduces blood pressure and helps patients achieve blood pressure targets. It also improves patient and physician satisfaction.
JOURNAL OF CLINICAL HYPERTENSION
(2023)
Article
Pharmacology & Pharmacy
Pranavkumar Shah, Bhavin Dhaduk
Summary: A simple, sensitive, and accurate in-vitro dissolution method has been developed based on USP dissolution testing methodologies for the analysis of Olmesartan Medoxomil (OLM), Chlorthalidone (CHLR), and Cilnidipine (CIL) drug combination.
CURRENT PHARMACEUTICAL ANALYSIS
(2022)
Article
Chemistry, Multidisciplinary
Hoda M. Marzouk, Sara El-Hanboushy, Reem H. Obaydo, Yasmin M. Fayez, Mohamed Abdelkawy, Hayam M. Lotfy
Summary: In this study, HPLC-DAD and LC-MS/MS methods were developed and validated for the concurrent determination of Hydrochlorothiazide and five antihypertensive drugs, as well as two impurities. The developed methods were in accordance with ICH guidelines. Additionally, the consumption of energy and solvents in the drug analysis needs to be considered.
Article
Pharmacology & Pharmacy
Xinjing Li, Enpan Mo, Lin Chen
Summary: This study evaluated the bioequivalence of olmesartan medoxomil/amlodipine besylate tablet and found that the absorption of olmesartan was significantly affected by food, while the absorption of amlodipine was not affected. The results showed that the test and reference formulations were bioequivalent with similar safety profiles.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT
(2022)
Article
Pharmacology & Pharmacy
Binny Mehta, Hirak Joshi, Ujash Shah, Pinak Patel
Summary: The study describes the RP-HPLC method for estimation of Olmesartan Medoxomil, Telmisartan, and Hydrochlorothiazide using QbD for data analysis. The research design is simple, rapid, accurate, and economical, conducted in India. QbD approach was applied for data analysis and method validation according to ICH guidelines.
JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL
(2021)
Article
Cardiac & Cardiovascular Systems
Alexander R. Zheutlin, Catherine G. Derington, Jordan B. King, Ransmond O. Berchie, Jennifer S. Herrick, Dave L. Dixon, Jordana B. Cohen, Daichi Shimbo, Ian M. Kronish, Joseph J. Saseen, Paul Muntner, Andrew E. Moran, Adam P. Bress
Summary: Combination antihypertensive therapy is underused, especially in certain race/ethnic groups, in the treatment of hypertension in the United States. Factors associated with monotherapy use despite uncontrolled blood pressure include higher systolic blood pressure, younger age, recent healthcare visits, higher body mass index, and the presence of heart failure.
AMERICAN HEART JOURNAL
(2022)
Article
Pharmacology & Pharmacy
Matrika Saha Roy, Rehnuma Tanjin, Tanmoy Debnath, Bidduth Kumar Sarkar, Prema Modak, Milon Mondal, Arghya Prosun Sarkar, Md Ariful Islam, Sukalyan Kumar Kundu
Summary: Combination therapy is popular for treating chronic diseases, but some fixed dose drug combinations may increase the risk of adverse effects. A study on an antihypertensive drug combination suggested no additional toxicity with long-term use. Computational simulations can provide valuable insights into potential toxicities of drug combinations.
FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES
(2021)
Article
Medicine, General & Internal
Piotr Jedrusik, Grzegorz Placha, Zbigniew Gaciong, AMCOR Trial Investigators
Summary: This study compared the antihypertensive effect and safety of bisoprolol 5 mg (BISO5mg) and amlodipine 5 mg (AMLO5mg) combination to AMLO5mg alone in hypertensive patients. The results showed that the bisoprolol-treated group had significant reductions in systolic and diastolic blood pressure compared to placebo, with a lower heart rate. Adding bisoprolol 5 mg to amlodipine 5 mg can improve blood pressure control.
CURRENT MEDICAL RESEARCH AND OPINION
(2023)
Review
Peripheral Vascular Disease
Michel Burnier, Josep Redon, Massimo Volpe
Summary: Blood pressure control is still a clinical need that has not been fully met. Combining drugs with complementary mechanisms of action, such as renin-angiotensin system (RAS) inhibitors, calcium channel blockers (CCBs), and diuretics, is recommended by international guidelines. Studies have shown that combining olmesartan (OM) with amlodipine (AML) or hydrochlorothiazide (HCTZ) provides additional benefits in blood pressure control in different patient populations. Additionally, OM-based single-pill combinations (SPCs) have been shown to improve therapeutic adherence and produce sustained and smoother blood pressure reduction compared to monotherapy or placebo.
HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION
(2023)
Article
Immunology
Jonathan S. Bromberg, Matthew R. Weir, A. Osama Gaber, Michael A. Yamin, Itzhak D. Goldberg, Tracy J. Mayne, Weizhong Cal, Matthew Cooper
Summary: This study showed that treatment with ANG-3777 in patients undergoing renal transplantation can improve renal function with a good safety profile compared to placebo.
Article
Urology & Nephrology
Emily A. Hu, Josef Coresh, Cheryl A. M. Anderson, Lawrence J. Appel, Morgan E. Grams, Deidra C. Crews, Katherine T. Mills, Jiang He, Julia Scialla, Mahboob Rahman, Sankar D. Navaneethan, James P. Lash, Ana C. Ricardo, Harold Feldman, Matthew R. Weir, Haochang Shou, Casey M. Rebholz
Summary: This study concluded that greater adherence to several healthy dietary patterns is associated with lower risk for CKD progression and all-cause mortality among people with CKD. Adopting healthy dietary patterns can be considered as a strategy for managing CKD.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2021)
Article
Urology & Nephrology
Matthew R. Weir, April Slee, Tao Sun, Dainius Balis, Richard Oh, Dick de Zeeuw, Vlado Perkovic
Summary: The study showed that there were no significant effects of canagliflozin on serum potassium levels in the overall population or key subgroups in the CANVAS Program. Adverse events of hyperkalemia were uncommon and occurred at comparable rates with canagliflozin and placebo.
CLINICAL KIDNEY JOURNAL
(2021)
Review
Medicine, General & Internal
Biff F. Palmer, Juan Jesus Carrero, Deborah J. Clegg, Gates B. Colbert, Michael Emmett, Steven Fishbane, Debra J. Hain, Edgar Lerma, Macaulay Onuigbo, Anjay Rastogi, Simon D. Roger, Bruce S. Spinowitz, Matthew R. Weir
Summary: Hyperkalemia is a common electrolyte abnormality that requires personalized monitoring and management. Further research is needed to promote more effective treatment of hyperkalemia.
MAYO CLINIC PROCEEDINGS
(2021)
Article
Surgery
Tracy J. Mayne, Robert J. Nordyke, Jesse D. Schold, Matthew R. Weir, Sumit Mohan
Summary: A 5 ml/min/1.73 m(2) difference in 12-month eGFR was consistently associated with around a 20% increase in death-censored graft failure risk, interpreted as clinically meaningful in renal transplantation clinical trials.
CLINICAL TRANSPLANTATION
(2021)
Editorial Material
Immunology
A. Benedict Cosimi, Nancy L. Ascher, Jean C. Emond, Dixon B. Kaufman, Joren C. Madsen, Joshua Miller, Anthony P. Monaco, Robert A. Montgomery, Kenneth A. Newell, Alberto Sanchez-Fueyo, Minnie M. Sarwal, John D. Scandling, Samuel Strober, Satoru Todo, Matthew R. Weir, David H. Sachs
Article
Medicine, Research & Experimental
Fatima Rodriguez, Donghyun J. Lee, Sanchit S. Gad, Matheus P. Santos, Robert J. Beetel, Joseph Vasey, Robert A. Bailey, Aarti Patel, Jaime Blais, Matthew R. Weir, Rajesh Dash
Summary: The study found significant delays in the diagnosis of diabetic kidney disease (DKD) and initiation of treatment with ACE inhibitors or ARBs, highlighting the need to improve diagnostic and treatment protocols for DKD. Many patients were not undergoing regular renal function testing, potentially resulting in missed opportunities for early diagnosis and treatment of the disease. Patients with DKD experienced delays in receiving appropriate treatment even after diagnosis.
ADVANCES IN THERAPY
(2021)
Article
Endocrinology & Metabolism
Matthew R. Weir, Jagadish Gogate, C. V. Damaraju, Ricardo Correa-Rotter, Kenneth W. Mahaffey
Summary: A post hoc analysis of integrated data from the CANVAS Program and CREDENCE trial found that canagliflozin reduced the risk of major adverse cardiovascular events (MACE) in Hispanic patients with type 2 diabetes and high cardiovascular risk or nephropathy, without heterogeneity by baseline estimated glomerular filtration rate (eGFR).
DIABETES OBESITY & METABOLISM
(2022)
Editorial Material
Urology & Nephrology
Eric J. Xu, LaPricia Lewis Boyer, Bernard G. Jaar, Patti L. Ephraim, Luis Gimenez, Alan Cheng, Jonathan Chrispin, Matthew R. Weir, Dominic Raj, Eliseo Guallar, Tariq Shafi
Summary: The study revealed that patients receiving dialysis and their family members have limited knowledge about the high risk of arrhythmia and sudden cardiac death, and express concerns about implantable cardiac monitors. They believe nephrologists would be the best source for education on these topics.
Article
Pharmacology & Pharmacy
Patrick Rossignol, Lea David, Christine Chan, Ansgar Conrad, Matthew R. Weir
Summary: Global pharmacovigilance data over 4 years confirmed that the tolerability and safety of patiromer in clinical practice is predictable and consistent with clinical trial data, with no evidence of any new safety signals to date.
DRUGS-REAL WORLD OUTCOMES
(2021)
Meeting Abstract
Peripheral Vascular Disease
Michael Weber, Ajay Kirtane, Matthew Weir, Martin Leon
JOURNAL OF HYPERTENSION
(2021)
Meeting Abstract
Medicine, General & Internal
Bettina J. Kraus, Matthew R. Weir, George L. Bakris, Michaela Mattheus, David Z. I. Cherney, Naveed Sattar, Hiddo J. L. Heerspink, Ivana Ritter, Maximilian von Eynatten, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Audrey Koitka-Weber
Article
Transplantation
Wen Yan Xie, Kevin Kim, Naeem Goussous, Cinthia B. Drachenberg, Joseph R. Scalea, Matthew R. Weir, Jonathan S. Bromberg
Summary: Using dd-cfDNA as a biomarker can help detect potential graft-injuring events post-organ transplant even when serum levels are low. The true nature of kidney injury may need further confirmation through renal biopsy.
TRANSPLANTATION DIRECT
(2021)
Article
Urology & Nephrology
Mary Hannan, Sajid Ansari, Natalie Meza, Amanda H. Anderson, Anand Srivastava, Sushrut Waikar, Jeanne Charleston, Matthew R. Weir, Jonathan Taliercio, Edward Horwitz, Milda R. Saunders, Katherine Wolfrum, Harold Feldman, James P. Lash, Ana C. Ricardo
Summary: The CRIC Study is an ongoing longitudinal study involving nearly 5500 adults with CKD in the United States, making significant contributions to understanding factors associated with CKD progression over the past 10 years. Findings from the study were grouped into six thematic categories, highlighting areas for future research and opportunities for interdisciplinary collaboration.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Meeting Abstract
Urology & Nephrology
Matthew Weir, Lea David, Christine Chan, Ansgar Conrad, Patrick Rossignol
AMERICAN JOURNAL OF KIDNEY DISEASES
(2021)